Sanofi-Aventis: Disappointment Over NV1FGF Drug Trial
September 22 2010 - 01:44AM
Dow Jones News
French drug company Sanofi-Aventis (SNY) said Wednesday a trial
of its NV1FGF drug has yielded disappointing results.
"The Phase III Tamaris trial evaluating the investigational
angiogenic therapy NV1FGF...did not meet its primary endpoint,"
Sanofi-Aventis said.
"The primary endpoint was to demonstrate the superiority of
NV1FGF over a placebo in the prevention of major amputation or
death from any cause over 12 months, whichever came first, in
critical limb ischemia patients who were not eligible for
revascularization," the company said.
"We are disappointed that NV1FGF failed to achieve significance
in the Tamaris trial, and for patients who are suffering from the
dramatic consequences of this disease and are hoping for new
treatments" said Marc Cluzel, executive vice president for research
and development at Sanofi-Aventis.
"We are evaluating all options on the NV1FGF development and
remain committed to innovation in diseases where there are major
healthcare needs and no therapeutic alternative," he added.
- By Adam Mitchell, Dow Jones Newswires, +33 1 40171756;
adam.mitchell@dowjones.com
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024